Table of contents
- Trial overview
- ALS study details
- Alzheimer’s disease study details
- What the trials measure
- Who can participate
- How the studies are designed
Trial overview
Two interventional studies are investigating VHB937, which means researchers are giving a study treatment and comparing the results with another group.[1][2] Both trials are in Phase 2, and both are authorised.[1][2]
One study is in people with amyotrophic lateral sclerosis (ALS), and the other is in people with Alzheimer’s disease.[1][2] These trials are designed to learn whether VHB937 may improve disease-related outcomes compared with placebo.[1][2]
ALS study details
The ALS trial is titled “A clinical trial to learn about the effects of VHB937 in people with amyotrophic lateral sclerosis (ALS).”[1] It plans to enroll 225 people and is authorised.[1]
This study compares VHB937 with placebo, which is a study infusion that does not contain the active trial drug and is used for fair comparison.[1] The brief summary says the goal is to compare the efficacy of VHB937 versus placebo on a composite of permanent assisted ventilation (PAV)-free survival and function in the double-blind period.[1]
The main outcome is the composite of PAV-free survival and change in ALSFRS-R, analysed using Combined Assessment of Function and Survival (CAFS) from baseline to double-blind week 40.[1] In simple terms, this means the study looks at both breathing-related survival and daily function together, not just one result alone.[1]
Alzheimer’s disease study details
The Alzheimer’s disease trial is titled “A clinical trial to learn about the effects of VHB937 in people with Alzheimer’s disease.”[2] It is also authorised and plans to enroll 407 people.[2]
This study compares VHB937 with placebo and is focused on cognition and function, meaning memory, thinking, and daily life abilities.[2] The trial uses an infusion form of the study treatment, as listed in the trial data.[2]
The primary outcome is the change from baseline to week 72 in the Clinical Dementia Rating scale – Sum of Boxes (CDR-SB).[2] This score helps researchers measure how Alzheimer’s disease changes thinking and daily function over time.[2]
What the trials measure
The ALS study focuses on a combined outcome, which is a way of putting two important results together: survival without permanent assisted ventilation and change in ALSFRS-R.[1] This helps researchers see whether treatment affects both life support needs and everyday function.[1]
The Alzheimer’s disease study measures change in CDR-SB from baseline to week 72.[2] This is a standard way to track how much the disease affects memory, thinking, and daily activities over time.[2]
Who can participate
Each trial is limited to one disease group: people with ALS for the first study and people with Alzheimer’s disease for the second study.[1][2] The trial data do not list the full eligibility rules, so the exact participation criteria are not shown here.[1][2]
Because these are disease-specific studies, a person would need to have the condition being studied and meet the study’s detailed requirements.[1][2]
How the studies are designed
Both studies are Phase 2 and interventional, which means they are testing a treatment in people and looking closely at whether it may help.[1][2] The ALS study includes a double-blind period, meaning the people in the study and the researchers do not know who is receiving VHB937 or placebo during that time.[1]
The trial records provide the main condition, phase, status, planned enrollment, intervention type, and primary outcome for each study.[1][2] They do not give detailed results yet, so these records describe ongoing research rather than final findings.[1][2]
